Newfeed

TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced receipt of a “Study May Proceed” letter from the U.S. F

Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2]Latest published local registry reported endometrial cancer as the fourth most common cancer and had the ninth highest cancer mortality rat

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: